



Docket No.: 066782-0056

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Customer Number: 41552
Mazar, Andrew P., et al. : Confirmation Number: 8000
Application No.: 10/655,201 : Group Art Unit: 1654
Filed: September 03, 2003 : Examiner: Christopher R. Tate
For: ANTI-INVASIVE AND ANTI- : CERTIFICATE OF MAILING (37 CFR § 1.8(a))
ANGIOGENIC COMPOSITIONS
AND METHODS

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail as First Class Mail under 37 CFR 1.8(a) in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Jan 13, 2005.

Sarah M. Hines

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. Five (5) of the references are enclosed. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account

No. 502624.

01/25/2005 HMEKONEN 00000058 502624 10655201

01 FC:1806 180.00 DA


Serial No.: 10/655,201

The references marked with asterisks (**) were cited by or submitted to the U.S. Patent and Trademark Office in parent application Serial No. 09/437,136, filed November 10, 1999, which is relied upon for an earlier filing date under 35 USC 120. Thus, copies of these references are not attached. 37 CFR 1.98(d).

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.


Respectfully submitted,

McDERMOTT WILL & EMERY LLP


Matthew V. Grumbling
Registration No. 44,427

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
Phone: 858.535.9001 MVG:cej
Facsimile: 858.597.1585
Date: January 13, 2005

**Please recognize our Customer No. 41552
as our correspondence address.**

INFORMATION DISCLOSURE CITATION IN AN APPLICATION				ATTY. DOCKET NO. 066782-0056		SERIAL NO. 10/655,201	
				APPLICANT Mazar, Andrew P., et al.			
				FILING DATE September 03, 2003		GROUP 1654	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Codez (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1	US 5,416,006	05/16/1995	Blasi et al.			
		US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number & Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
	**2	WO 97/25422	07/17/1997			Yes	No
	**3	WO 90/12872	11/01/1990				
	**4	WO 97/05257	02/13/1997				
	**5	WO 94/28014	12/08/1994				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	**6	Brynestad et al., "Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines," <u>J Virol.</u> 64(2):680-685 (1990).					
	**7	Chambers et al., "Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase," <u>Cancer Res.</u> 55(7):1578-1585 (1995).					
	**8	Claeson G., "Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system," <u>Blood Coagul Fibrinolysis.</u> 5(3):411-436 (1994).					
✓	9	Higazi et al., "Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor," <u>J Biol Chem.</u> 270(29):17375-17380 (1995).					
✓	10	Higazi et al., "Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1," <u>Blood.</u> 87(9):3545-9 (1996).					
✓	11	Higazi et al., "Lysis of plasma clots by urokinase-soluble urokinase receptor complexes," <u>Blood.</u> 92(6):2075-2083 (1998).					
	**12	Hoosein et al., "Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines," <u>Cancer Commun.</u> 3(8):255-264 (1991).					
	**13	Hruby VJ., "Conformational and topographical considerations in the design of biologically active peptides," <u>Biopolymers.</u> 33(7):1073-1082 (1993).					

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

**References cited in parent application.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. 066782-0056	SERIAL NO. 10/655,201
		APPLICANT Mazar, Andrew P., et al.	
		FILING DATE September 03, 2003	GROUP 1654
	**14	Kempf DJ., "Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease," <u>Methods Enzymol.</u> 241:334-354 (1994).	
✓	15	Manchanda et al., "Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes," <u>J Biol Chem.</u> 266(22):14580-14584 (1991).	
	**16	Min et al., "Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice," <u>Cancer Res.</u> 56(10):2428-2433 (1996).	
	**17	Odedra et al., "Low molecular weight angiogenesis factors," <u>Pharmacol Ther.</u> 49(1-2):111-24 (1991).	
	**18	Parish et al., "A basement-membrane permeability assay which correlates with the metastatic potential of tumour cells," <u>Int J Cancer.</u> 52(3):378-383 (1992).	
	**19	Rabbani et al., "Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA)," <u>Int J Cancer.</u> 63(6):840-845 (1995).	
	**20	Schnaper et al., "Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways," <u>J Cell Physiol.</u> 165(1):107-118 (1995).	
	**21	Smith E.A.: "Peptides, chemistry and biology, Proceedings 12 th APS, 1991 Cambridge" 1992, ESCOM, LEIDEN XP002083073 Lie e.a.: The inhibition of fibrin stimulated .tau.-PA-induced plasminogen activation by the A chain fragment 149-157 or urokinase; see pp. 810-811, esp. table 1.	
	**22	Wiley et al., "Peptidomimetics derived from natural products," <u>Med Res Rev.</u> 13(3):327-384 (1993).	

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

**References cited in parent application.